Kari Hill, NP
Nurse Practitioner · Spring Lake, MINPI 1184024481
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $371,583 of the $426,354 with a category attached, or 87.2%. AstraZeneca accounts for 74.6% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $173,235, 5.2 times the $33,225 reported in 2021. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 848 payments — averaging $502.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$318K
- Regeneron Healthcare Solutions, Inc.$66K
- Sanofi$41K
- GSK$662
- Amgen$250
- Boehringer Ingelheim$106
- plus $338 from 8 others
What the payments were for
- Consulting fees$11,1043%
- Speaking & faculty fees$371,58387%
- Travel & lodging$28,9937%
- Food & beverage$14,5763%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 586 | $317,938 |
| Regeneron Healthcare Solutions, Inc. | 109 | $65,697 |
| Sanofi | 99 | $41,363 |
| GSK | 31 | $662 |
| Amgen | 3 | $250 |
| Boehringer Ingelheim | 6 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Insmed, Inc. | 4 | $66 |
| Grifols USA, LLC | 2 | $56 |
| Genentech USA, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Verona Pharma, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Inogen, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$426,354 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 729 | $542,732 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 526 | $414,401 |
| Dupixent PenDupilumab | 47 | $178,060 |
| TezspireTezepelumab-Ekko | 22 | $92,383 |
| Fasenra PenBenralizumab | 15 | $81,044 |
| NucalaMepolizumab | 20 | $68,367 |
| Spiriva RespimatTiotropium Bromide | 63 | $41,825 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 144 | $32,553 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 744 | $27,588 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 80 | $24,360 |
| DuleraMometasone/Formoterol | 37 | $21,333 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $18,045 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $18,027 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $17,930 |
| Atrovent HfaIpratropium Bromide | 26 | $17,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $317,938 | $659,378806 claims |
| GSKTrelegy Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $662 | $538,371650 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $106 | $75,631133 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $27 | $16,22449 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Spring Lake
- Davida KrugerDetroit$739K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
- Debra DegraffGrand Rapids$80K
- Claudia Rivera-SalasEast Lansing$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.